About Nucleus Genomics
Nucleus Genomics is a company based in Manhattan (United States) founded in 2021 by Kian Sadeghi.. Nucleus Genomics has raised $31.5 million across 3 funding rounds from investors including Neo, Seven Seven Six and Balaji Srinivasan. Nucleus Genomics has completed 2 acquisitions, including Cambrean and Impute.me. Nucleus Genomics offers products and services including DNA Health Test and Whole-Genome Test. Nucleus Genomics operates in a competitive market with competitors including ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others.
- Headquarter Manhattan, United States
- Founders Kian Sadeghi
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nucleus Genomics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nucleus Genomics
Nucleus Genomics offers a comprehensive portfolio of products and services, including DNA Health Test and Whole-Genome Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Analyzes genetic risks for over 900 health conditions including cancers.
Sequences full genome for insights on diseases and longevity factors.
Unlock access to complete
Funding Insights of Nucleus Genomics
Nucleus Genomics has successfully raised a total of $31.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $14.0M
-
First Round
First Round
(15 Dec 2021)
- Investors Count 26
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series A - Nucleus Genomics | Valuation |
investors |
|
| Jul, 2022 | Amount | Series A - Nucleus Genomics | Valuation |
investors |
|
| Dec, 2021 | Amount | Seed - Nucleus Genomics | Valuation | Founders Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nucleus Genomics
Nucleus Genomics has secured backing from 26 investors, including venture fund and angel investors. Prominent investors backing the company include Neo, Seven Seven Six and Balaji Srinivasan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on investing in technology startups
|
Founded Year | Domain | Location | |
|
Technology startups are accelerated and incubated sector-agnostically by Neo.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in deep tech innovations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nucleus Genomics
Nucleus Genomics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cambrean and Impute.me. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Digital health analytics for businesses are provided via a platform.
|
2021 | ||||
|
Non-profit tools utilizing data services are provided by Impute.me.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nucleus Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nucleus Genomics Comparisons
Competitors of Nucleus Genomics
Nucleus Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Natera, Variantyx, ImaginAb and RareCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics data analysis platform for healthcare diagnostics is offered.
|
|
| domain | founded_year | HQ Location |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| domain | founded_year | HQ Location |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| domain | founded_year | HQ Location |
Genetic sequencing is provided for late-stage cancer patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nucleus Genomics
Frequently Asked Questions about Nucleus Genomics
When was Nucleus Genomics founded?
Nucleus Genomics was founded in 2021.
Where is Nucleus Genomics located?
Nucleus Genomics is headquartered in Manhattan, United States. It is registered at Manhattan, New York, United States.
Who is the current CEO of Nucleus Genomics?
Kian Sadeghi is the current CEO of Nucleus Genomics. They have also founded this company.
Is Nucleus Genomics a funded company?
Nucleus Genomics is a funded company, having raised a total of $31.5M across 3 funding rounds to date. The company's 1st funding round was a Seed of $3.5M, raised on Dec 15, 2021.
What does Nucleus Genomics do?
Nucleus Genomics was established in 2021 in Manhattan, United States, within the genomics sector. A direct-to-consumer platform is operated, where whole-genome sequencing is utilized to deliver genetic risk and disposition score analyses. These services cover an extensive array of diseases and traits, with a focus on rare variant detection through at-home testing kits. Operations are centered on accessible genetic insights for individual users.
Who are the top competitors of Nucleus Genomics?
Nucleus Genomics's top competitors include Natera, ImaginAb and Lantern Pharma.
What products or services does Nucleus Genomics offer?
Nucleus Genomics offers DNA Health Test and Whole-Genome Test.
How many acquisitions has Nucleus Genomics made?
Who are Nucleus Genomics's investors?
Nucleus Genomics has 26 investors. Key investors include Neo, Seven Seven Six, Balaji Srinivasan, Achal Upadhyaya, and Giant Step Capital.